Phase 2 Thyroid Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and sign a consent form and are willing to follow all trial requirements
• Adults between 18 and 80 years old (inclusive) at the time of signing the consent form
• People with an advanced solid tumour confirmed by tissue or cell testing, where standard treatments have stopped working, are not tolerated, or no effective standard treatment exists — this includes cancers such as soft tissue sarcoma, thyroid cancer, colorectal cancer, pancreatic cancer, breast cancer, gastric cancer, cervical cancer, lung cancer, head and neck cancer, liver cancer, bile duct cancer, kidney cancer, prostate cancer, vulvar cancer, and others
• People who have at least one tumour that can be measured according to standard imaging guidelines (RECIST v1.1), and that tumour has not been treated with radiotherapy (unless it has clearly grown back after radiotherapy) and has not had a tissue biopsy taken within 7 days before screening
• People who have at least one tumour that a doctor judges to be suitable for repeated direct injection (either by hand or with the help of medical imaging tools)
• People whose physical functioning score (ECOG scale) is rated 0 or 1 within 7 days before the first dose — meaning they are fully active or restricted in physically strenuous activity but able to carry out light work
• People with an expected survival of at least 3 months
• People whose side effects from previous treatments have largely resolved to a mild level (grade 1 or below on a standard medical scale) before the screening visit, with some exceptions allowed at the doctor's discretion (such as hair loss or mild nerve-related symptoms)
• People whose heart pumping function (left ventricular ejection fraction) is at least 50%
• People whose blood counts, kidney function, liver function, and blood clotting results meet specific laboratory thresholds within 7 days before the first dose (confirm with trial site for exact values)
• Women of childbearing potential who have a negative pregnancy test within 7 days before the first dose, are not breastfeeding, and commit to using effective contraception or abstaining from sex during treatment and for 6 months after treatment ends
• Male participants who commit to using effective contraception or abstaining from sex during treatment and for 6 months after treatment ends, and who agree not to donate sperm during this period

Who may not be able to join:

• People with a current or previous condition causing abnormal iron metabolism (such as thalassemia or G6PD deficiency), except those with iron deficiency anaemia
• People who have had or currently have signs of a hollow organ perforation at or near the planned injection site
• People whose planned injection site has skin breakdown, redness, swelling, tissue death, or bleeding that would make injection of the study drug difficult
• People who have received systemic chemotherapy, targeted therapy, anti-tumour biological therapy, or immunotherapy within 3 weeks before the first dose; or radiotherapy within 14 days before the first dose (or within 28 days if the radiotherapy was to the brain or spinal cord); or certain traditional Chinese medicines with anti-tumour indications within 2 weeks before the first dose
• People who have had major surgery within 4 weeks before the first dose, or who have wounds, ulcers, or fractures that have not fully healed (minor surgeries with full recovery within 1 week may be an exception — confirm with trial site)
• People with untreated or active cancer that has spread to the brain or spinal cord, or with carcinomatous meningitis, unless these have been treated and have been stable for at least 4 weeks, with no brain swelling and no need for steroid treatment
• People with high blood pressure that is not well controlled (for example, consistently above 160/100 mmHg)
• People with cancer-related pain that is not under control
• People with fluid build-up around the lungs, heart, or in the abdomen that needs to be drained more than once a month
• People who have had another active cancer diagnosis within the past 5 years, with some exceptions including certain early-stage or in-situ cancers that have been fully treated (confirm with trial site)
• People who have received a live virus vaccine within 4 weeks before the first dose (note: standard injected flu vaccines are generally permitted, but nasal spray flu vaccines are not)
• People with a history of immune deficiency conditions (including HIV-positive status), congenital or acquired immune deficiency diseases, or a history of organ transplantation
• People with active hepatitis B (with certain virus levels above a set threshold), active hepatitis C (confirmed by specific blood tests), or a positive HIV antibody test
• People with a severe ongoing infection (such as tuberculosis) that requires systemic antibiotic, antifungal, or antiviral treatment before starting the study (note: antiviral treatment for viral hepatitis is generally allowed — confirm with trial site)
• People with a history of serious heart problems within the past 6 months, including heart attack, severe heart failure, unstable chest pain, serious heart rhythm problems requiring treatment, stroke, or mini-stroke; or a history of certain dangerous heart rhythm abnormalities
• People with an active and serious psychiatric condition such as schizophrenia, major depression, or bipolar disorder
• People known to be allergic or intolerant to any ingredient in the study drug
• People who have taken part in another interventional clinical trial within 3 weeks before the start of this study
• People who the doctor judges to be unsuitable for other reasons not listed above

Important: Always verify eligibility with the trial site directly before applying.